Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer

G. Zanetta, F. Fei, G. Parma, M. Balestrino, A. Lissoni, A. Gabriele, C. Mangioni

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Purpose: The results of salvage chemotherapy for recurrent or persistent squamous-cell cervical cancer are unsatisfactory. Cisplatin and Ifosfamide are effective compounds in cervical cancer. Paclitaxel has recently been tested with promising results. The aim of this study was to assess the efficacy of a combination of paclitaxel, ifosfamide and cisplatin (TIP) for persistent/recurrent squamous-cell cervical carcinoma in a phase II trial. Patients and methods: Forty-five women were treated with the TIP regimen. Thirty-one had received prior irradiation. Paclitaxel was given at a dose of 175 mg/m2, ifosfamide at a dose of 5 g/m2, and cisplatin at a dose of 75 mg/m2 (50 mg/m2 in irradiated patients) at three-week intervals. Results: We observed 15 clinical complete responses, 15 partial responses, 9 stable diseases and 6 progressions. The objective response rate was 67% (95% confidence interval: 51%-81%). Ten complete responders underwent subsequent surgery and seven had pathology-defined complete responses (two in irradiated areas). The response rate was 52% in irradiated and 75% in non-irradiated areas. The median survival for non-responders is 6 months, 9+ month for partial responders and 13+ for complete responders. The most relevant side effect was myelotoxicity, with 91% of patients experiencing grade 3-4. One woman had life-threatening toxic effects. Conclusions: This combination is highly effective for salvage treatment in non-irradiated patients. For irradiated women the response rate is higher than that observed with other regimens but further investigation is warranted. The toxicity is relevant but adequate hydration and prolonged infusion of ifosfamide make it acceptable.

Original languageEnglish
Pages (from-to)1171-1174
Number of pages4
JournalAnnals of Oncology
Volume10
Issue number10
DOIs
Publication statusPublished - 1999

Fingerprint

Squamous Cell Neoplasms
Ifosfamide
Uterine Cervical Neoplasms
Drug Therapy
Paclitaxel
Cisplatin
Salvage Therapy
Poisons
Disease Progression
Squamous Cell Carcinoma
Confidence Intervals
Pathology
Survival
TP protocol

Keywords

  • Cervical cancer
  • Chemotherapy
  • Cisplatin
  • Ifosfamide
  • Paclitaxel
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. / Zanetta, G.; Fei, F.; Parma, G.; Balestrino, M.; Lissoni, A.; Gabriele, A.; Mangioni, C.

In: Annals of Oncology, Vol. 10, No. 10, 1999, p. 1171-1174.

Research output: Contribution to journalArticle

Zanetta, G. ; Fei, F. ; Parma, G. ; Balestrino, M. ; Lissoni, A. ; Gabriele, A. ; Mangioni, C. / Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. In: Annals of Oncology. 1999 ; Vol. 10, No. 10. pp. 1171-1174.
@article{640fa5ca393f4b22a93c439a217a1333,
title = "Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer",
abstract = "Purpose: The results of salvage chemotherapy for recurrent or persistent squamous-cell cervical cancer are unsatisfactory. Cisplatin and Ifosfamide are effective compounds in cervical cancer. Paclitaxel has recently been tested with promising results. The aim of this study was to assess the efficacy of a combination of paclitaxel, ifosfamide and cisplatin (TIP) for persistent/recurrent squamous-cell cervical carcinoma in a phase II trial. Patients and methods: Forty-five women were treated with the TIP regimen. Thirty-one had received prior irradiation. Paclitaxel was given at a dose of 175 mg/m2, ifosfamide at a dose of 5 g/m2, and cisplatin at a dose of 75 mg/m2 (50 mg/m2 in irradiated patients) at three-week intervals. Results: We observed 15 clinical complete responses, 15 partial responses, 9 stable diseases and 6 progressions. The objective response rate was 67{\%} (95{\%} confidence interval: 51{\%}-81{\%}). Ten complete responders underwent subsequent surgery and seven had pathology-defined complete responses (two in irradiated areas). The response rate was 52{\%} in irradiated and 75{\%} in non-irradiated areas. The median survival for non-responders is 6 months, 9+ month for partial responders and 13+ for complete responders. The most relevant side effect was myelotoxicity, with 91{\%} of patients experiencing grade 3-4. One woman had life-threatening toxic effects. Conclusions: This combination is highly effective for salvage treatment in non-irradiated patients. For irradiated women the response rate is higher than that observed with other regimens but further investigation is warranted. The toxicity is relevant but adequate hydration and prolonged infusion of ifosfamide make it acceptable.",
keywords = "Cervical cancer, Chemotherapy, Cisplatin, Ifosfamide, Paclitaxel, Survival",
author = "G. Zanetta and F. Fei and G. Parma and M. Balestrino and A. Lissoni and A. Gabriele and C. Mangioni",
year = "1999",
doi = "10.1023/A:1008362814642",
language = "English",
volume = "10",
pages = "1171--1174",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "10",

}

TY - JOUR

T1 - Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer

AU - Zanetta, G.

AU - Fei, F.

AU - Parma, G.

AU - Balestrino, M.

AU - Lissoni, A.

AU - Gabriele, A.

AU - Mangioni, C.

PY - 1999

Y1 - 1999

N2 - Purpose: The results of salvage chemotherapy for recurrent or persistent squamous-cell cervical cancer are unsatisfactory. Cisplatin and Ifosfamide are effective compounds in cervical cancer. Paclitaxel has recently been tested with promising results. The aim of this study was to assess the efficacy of a combination of paclitaxel, ifosfamide and cisplatin (TIP) for persistent/recurrent squamous-cell cervical carcinoma in a phase II trial. Patients and methods: Forty-five women were treated with the TIP regimen. Thirty-one had received prior irradiation. Paclitaxel was given at a dose of 175 mg/m2, ifosfamide at a dose of 5 g/m2, and cisplatin at a dose of 75 mg/m2 (50 mg/m2 in irradiated patients) at three-week intervals. Results: We observed 15 clinical complete responses, 15 partial responses, 9 stable diseases and 6 progressions. The objective response rate was 67% (95% confidence interval: 51%-81%). Ten complete responders underwent subsequent surgery and seven had pathology-defined complete responses (two in irradiated areas). The response rate was 52% in irradiated and 75% in non-irradiated areas. The median survival for non-responders is 6 months, 9+ month for partial responders and 13+ for complete responders. The most relevant side effect was myelotoxicity, with 91% of patients experiencing grade 3-4. One woman had life-threatening toxic effects. Conclusions: This combination is highly effective for salvage treatment in non-irradiated patients. For irradiated women the response rate is higher than that observed with other regimens but further investigation is warranted. The toxicity is relevant but adequate hydration and prolonged infusion of ifosfamide make it acceptable.

AB - Purpose: The results of salvage chemotherapy for recurrent or persistent squamous-cell cervical cancer are unsatisfactory. Cisplatin and Ifosfamide are effective compounds in cervical cancer. Paclitaxel has recently been tested with promising results. The aim of this study was to assess the efficacy of a combination of paclitaxel, ifosfamide and cisplatin (TIP) for persistent/recurrent squamous-cell cervical carcinoma in a phase II trial. Patients and methods: Forty-five women were treated with the TIP regimen. Thirty-one had received prior irradiation. Paclitaxel was given at a dose of 175 mg/m2, ifosfamide at a dose of 5 g/m2, and cisplatin at a dose of 75 mg/m2 (50 mg/m2 in irradiated patients) at three-week intervals. Results: We observed 15 clinical complete responses, 15 partial responses, 9 stable diseases and 6 progressions. The objective response rate was 67% (95% confidence interval: 51%-81%). Ten complete responders underwent subsequent surgery and seven had pathology-defined complete responses (two in irradiated areas). The response rate was 52% in irradiated and 75% in non-irradiated areas. The median survival for non-responders is 6 months, 9+ month for partial responders and 13+ for complete responders. The most relevant side effect was myelotoxicity, with 91% of patients experiencing grade 3-4. One woman had life-threatening toxic effects. Conclusions: This combination is highly effective for salvage treatment in non-irradiated patients. For irradiated women the response rate is higher than that observed with other regimens but further investigation is warranted. The toxicity is relevant but adequate hydration and prolonged infusion of ifosfamide make it acceptable.

KW - Cervical cancer

KW - Chemotherapy

KW - Cisplatin

KW - Ifosfamide

KW - Paclitaxel

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0032744560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032744560&partnerID=8YFLogxK

U2 - 10.1023/A:1008362814642

DO - 10.1023/A:1008362814642

M3 - Article

C2 - 10586332

AN - SCOPUS:0032744560

VL - 10

SP - 1171

EP - 1174

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -